These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 8386751)

  • 1. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study.
    Bajorin DF; Sarosdy MF; Pfister DG; Mazumdar M; Motzer RJ; Scher HI; Geller NL; Fair WR; Herr H; Sogani P
    J Clin Oncol; 1993 Apr; 11(4):598-606. PubMed ID: 8386751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial.
    Horwich A; Sleijfer DT; Fosså SD; Kaye SB; Oliver RT; Cullen MH; Mead GM; de Wit R; de Mulder PH; Dearnaley DP; Cook PA; Sylvester RJ; Stenning SP
    J Clin Oncol; 1997 May; 15(5):1844-52. PubMed ID: 9164194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors.
    Kondagunta GV; Bacik J; Bajorin D; Dobrzynski D; Sheinfeld J; Motzer RJ; Bosl GJ
    J Clin Oncol; 2005 Dec; 23(36):9290-4. PubMed ID: 16361627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group.
    Siegert W; Beyer J; Strohscheer I; Baurmann H; Oettle H; Zingsem J; Zimmermann R; Bokemeyer C; Schmoll HJ; Huhn D
    J Clin Oncol; 1994 Jun; 12(6):1223-31. PubMed ID: 7911158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin-etoposide and carboplatin-etoposide induction chemotherapy for good-risk patients with germ cell tumors.
    Tjulandin SA; Garin AM; Mescheryakov AA; Perevodchikova NI; Gorbunova VA; Sokolov AV; Ljubimova NV; Mironova GT; Molchanov GV; Ozols RF
    Ann Oncol; 1993 Sep; 4(8):663-7. PubMed ID: 8240996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group.
    Lorch A; Kollmannsberger C; Hartmann JT; Metzner B; Schmidt-Wolf IG; Berdel WE; Weissinger F; Schleicher J; Egerer G; Haas A; Schirren R; Beyer J; Bokemeyer C; Rick O;
    J Clin Oncol; 2007 Jul; 25(19):2778-84. PubMed ID: 17602082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support.
    Margolin K; Doroshow JH; Ahn C; Hamasaki V; Leong L; Morgan R; Raschko J; Shibata S; Somlo G; Tetef M
    J Clin Oncol; 1996 Oct; 14(10):2631-7. PubMed ID: 8874321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lowered Cisplatin Dose and No Bleomycin in the Treatment of Pediatric Germ Cell Tumors: Results of the GCT-99 Protocol From the Brazilian Germ Cell Pediatric Oncology Cooperative Group.
    Lopes LF; Macedo CR; Aguiar Sdos S; Barreto JH; Martins GE; Sonaglio V; Milone M; Lima ER; Almeida MT; Lopes PM; Watanabe FM; D'Andrea ML; Pianovski MA; Melaragno R; Vianna SM; Moreira ME; Bruniera P; de Oliveira CZ
    J Clin Oncol; 2016 Feb; 34(6):603-10. PubMed ID: 26729441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors.
    Motzer RJ; Mazumdar M; Bajorin DF; Bosl GJ; Lyn P; Vlamis V
    J Clin Oncol; 1997 Jul; 15(7):2546-52. PubMed ID: 9215823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etoposide plus carboplatin or cisplatin in good-risk patients with germ cell tumors: a randomized comparison.
    Bosl GJ; Bajorin DF
    Semin Oncol; 1994 Oct; 21(5 Suppl 12):61-4. PubMed ID: 7992068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors.
    Bosl GJ; Geller NL; Bajorin D; Leitner SP; Yagoda A; Golbey RB; Scher H; Vogelzang NJ; Auman J; Carey R
    J Clin Oncol; 1988 Aug; 6(8):1231-8. PubMed ID: 2457657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
    Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
    Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk-adapted chemotherapy of germ cell tumors with carboplatin, etoposide and bleomycin for low-risk and cisplatin, etoposide and ifosfamide for high-risk patients. A single-center study.
    Tscherry G; Jacky E; Jost LM; Stahel RA
    Oncology; 2000 Aug; 59(2):110-7. PubMed ID: 10971168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors.
    Motzer RJ; Mazumdar M; Gulati SC; Bajorin DF; Lyn P; Vlamis V; Bosl GJ
    J Natl Cancer Inst; 1993 Nov; 85(22):1828-35. PubMed ID: 7693955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors.
    Motzer RJ; Gulati SC; Tong WP; Menendez-Botet C; Lyn P; Mazumdar M; Vlamis V; Lin S; Bosl GJ
    Cancer Res; 1993 Aug; 53(16):3730-5. PubMed ID: 8393380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors.
    Bokemeyer C; Köhrmann O; Tischler J; Weissbach L; Räth U; Haupt A; Schöffski P; Harstrick A; Schmoll HJ
    Ann Oncol; 1996 Dec; 7(10):1015-21. PubMed ID: 9037359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modified cisplatin, etoposide (or vinblastine) and ifosfamide salvage therapy for male germ-cell tumors. Long-term results.
    Pizzocaro G; Salvioni R; Piva L; Faustini M; Nicolai N; Gianni L
    Ann Oncol; 1992 Mar; 3(3):211-6. PubMed ID: 1316779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized trial of cisplatin, vinblastine, and bleomycin versus vinblastine, cisplatin, and etoposide in the treatment of advanced germ cell tumors of the testis: a Southwest Oncology Group study.
    Wozniak AJ; Samson MK; Shah NT; Crawford ED; Ford CD; Altman SJ; Stephens RL; Natale RB; Bouroncle BA; Blumenstein BA
    J Clin Oncol; 1991 Jan; 9(1):70-6. PubMed ID: 1702148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of bleomycin on retroperitoneal histology at post-chemotherapy retroperitoneal lymph node dissection of good risk germ cell tumors.
    Cary KC; Pedrosa JA; Kaimakliotis HZ; Masterson TA; Einhorn LH; Foster RS
    J Urol; 2015 Feb; 193(2):507-12. PubMed ID: 25254937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A medical research council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. MRC Testicular Tumour Working Party.
    Horwich A; Oliver RT; Wilkinson PM; Mead GM; Harland SJ; Cullen MH; Roberts JT; Fossa SD; Dearnaley DP; Lallemand E; Stenning SP;
    Br J Cancer; 2000 Dec; 83(12):1623-9. PubMed ID: 11104556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.